Palomar Medical Technologies (Nasdaq: PMTI) reported earnings on May 2. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Palomar Medical Technologies beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share increased to zero. GAAP loss per share contracted.

Gross margins dropped, operating margins increased, net margins increased.

Revenue details
 Palomar Medical Technologies reported revenue of $23.2 million. The two analysts polled by S&P Capital IQ expected to see revenue of $20.3 million on the same basis. GAAP reported sales were 22% higher than the prior-year quarter's $19.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.00. The two earnings estimates compiled by S&P Capital IQ predicted -$0.01 per share. Non-GAAP EPS dropped to zero from the prior-year quarter's $0.00. GAAP EPS were -$0.06 for Q1 compared to -$0.12 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 56.3%, 100 basis points worse than the prior-year quarter. Operating margin was -4.0%, 820 basis points better than the prior-year quarter. Net margin was -4.8%, 730 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $21.1 million. On the bottom line, the average EPS estimate is $0.03.

Next year's average estimate for revenue is $88.6 million. The average EPS estimate is $0.18.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 499 members out of 529 rating the stock outperform, and 30 members rating it underperform. Among 133 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 127 give Palomar Medical Technologies a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Palomar Medical Technologies is hold, with an average price target of $11.00.

Is Palomar Medical Technologies the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.